MOLECULAR CANCER THERAPEUTICS

TABLE OF CONTENTS

HIGHLIGHTS
623 Selected Articles from This Issue

MCT FIRST DISCLOSURES
625 F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd

Joel Morris, Donn G. Wishka, Omar D. Lopez, Vladimir Rudchenko, Guangfei Huang, Sierra N. Hoffman, Suzanne Borgel, Kyle Georgius, Jerry M. Collins, Melinda G. Hollingshead, and Beverly A. Teicher

REVIEW
632 Role of Polo-Like Kinase 4 (PLK4) in Epithelial Cancers and Recent Progress in Its Small Molecule Targeting for Cancer Management

Debra R. Garvey, Gagan Chhabra, Mary A. Ndiaye, and Nihal Ahmad

SMALL MOLECULE THERAPEUTICS
641 ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer

Jens Köhler, Yutong Zhao, Jiaqi Li, Prafulla C. Gokhale, Hong L. Tiv, Aine R. Knott, Margaret K. Wilkens, Kara M. Soroko, Mika Lin, Chiara Ambrogio, Monica Musteant, Atsuko Ogino, Jihyun Choi, Magda Bahcall, Arrien A. Bertram, Emily S. Chambers, Cloud P. Paveletz, Shripad A. Vasudevan, Jason R. Manro, Ramon V. Tiu, and Pasi A. Jänne

655 Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer

Elizabeth A. Wilson, Nahid Sultana, Khyati N. Shah, Howard L. Elford, and Jesika S. Faridi

665 ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2

Rozita Bagheri-Yarmand, Ramona Dadu, Lei Ye, Yaashmin Shiny Jebraj, Jade A. Martinez, Junsheng Ma, Rohinton S. Tarapore, Joshua E. Allen, Steven I. Sherman, Michelle D. Williams, and Robert F. Gagel

676 PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation

Mario Scarpa, Prerna Singh, Christopher M. Bailey, Jonelle K. Lee, Shivani Kapoor, Rena G. Lapidus, Sandrine Niyongere, Jaya Sangodkar, Yin Wang, Danilo Perrotti, Goutham Narla, and Maria R. Baer

681 Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer

Elizabeth A. Wilson, Nahid Sultana, Khyati N. Shah, Howard L. Elford, and Jesika S. Faridi

691 Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

Shogo Shigeta, Goldie Y.L. Lui, Reid Shaw, Russell Moser, Kay E. Gurley, Grace Durenberger, Rachele Rosati, Robert L. Diaz, Tan A. Ince, Elizabeth M. Swisher, Carla Grandori, and Christopher J. Kemp

704 Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK

David K. Lau, Ian Y. Luk, Laura J. Jenkins, Andrew Martin, David S. Williams, Kael L. Schoffer, Fiona Chionh, Michael Buchert, Katrin Sjoquist, Alex Boussiotas, Sarah A. Hayes, Matthias Ernst, Andrew J. Weickhardt, Nick Pavlakis, Niall C. Tebbutt, and John M. Mariadason

LARGE MOLECULE THERAPEUTICS
716 Anti-LYPD1/CDS T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer

Amy A. Lo, Jennifer Johnston, Ji Li, Danielle Mandikian, Maria Hristopoulou, Robyn Clark, Dorothee Nickles, Wei-Ching Liang, Kathy Hötzel, Debra Dunlap, Thinh Pham, Hao Cai, Meric Ovacik, Daniel Bravo-Perez, Elaine Mai, Dionysos Slaga, Diego Ellerman, James Ziia, Klara Totspl, Genee Lee, C. Andrew Boswell, Jian Payandeh, Yan Wu, and Teemu T. Junttila
# TABLE OF CONTENTS

## CANCER BIOLOGY AND TRANSLATIONAL STUDIES

**726**  

## MODELS AND TECHNOLOGIES

**749**  
Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies  
William G. Herrick, Casey L. Kilpatrick, Melinda G. Hollingshead, Dominic Esposito, Geraldine O’Sullivan Coyne, Andrea M. Gross, Barry C. Johnson, Alice P. Chen, Brigette C. Widemann, James H. Doroshow, Ralph E. Parchment, and Apurva K. Srivastava

## ABOUT THE COVER

In this issue of *Molecular Cancer Therapeutics*, Morris and colleagues disclose a novel fluorine-containing cytidine analog, F-aza-T-dCyd. F-aza-T-dCyd produced complete regressions in the HL-60 model pictured, as well as in xenografts of bladder and colon cancer. Their disclosure supports the continued development of F-aza-T-dCyd as a new therapeutic in a category that has seen five FDA approvals. Read the full manuscript on page 625.
Molecular Cancer Therapeutics

20 (4)

Mol Cancer Ther 2021;20:623-760.

| Updated version | Access the most recent version of this article at: http://mct.aacrjournals.org/content/20/4 |

| E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions | To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/20/4. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site. |